Spero Biopharma

Company Overview

Snapshot

Founded in June 2019 by Moti Hacham and Marta Weinstock-Rosin, Spero Biopharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of an innovative drug to prevent the deterioration from mild cognitive impairment to Alzheimer's disease.

Business overview

Spero Biopharma is a Health Tech & Life Sciences company specializing in the Pharmaceuticals sector. The company is developing Ladostigil, a drug designed to treat mild cognitive impairment before it progresses to Alzheimer's disease. Its core technology is focused on drug discovery within neurology, targeting the pharmaceutical industry in markets such as the United States.

Company Intelligence Q&A

What is Spero Biopharma's primary focus?

Spero Biopharma is focused on the prevention and treatment of Alzheimer's disease, specifically developing a drug to address mild cognitive impairment.

Who founded Spero Biopharma?

Spero Biopharma was founded by Moti Hacham and Marta Weinstock-Rosin in June 2019.

What is the key product under development at Spero Biopharma?

Spero Biopharma is developing Ladostigil, a drug intended to treat mild cognitive impairment before it advances to Alzheimer's disease.

In which stage of development is Spero Biopharma's product?

Spero Biopharma's product, Ladostigil, is currently in the Clinical Trial stage.

What is Spero Biopharma's current funding stage?

Spero Biopharma is currently in the Pre-Funding stage, indicating it has not yet raised external capital as of its last update in March 2021.